SK Biophama Presses Ahead with Opakalim License Deal Despite FDA Hold
SK Biopharmaceuticals, which is pursuing a licensing deal worth up to 1.1 trillion won ($816.75 million) for an epilepsy drug candidate, has encountered an unexpected hurdle after the U.S. Food and Drug Administration (FDA) placed the candidate under a partial clinical hold. The company, however, pl
We haven't written up this one. BusinessKorea has the full story — the link below goes straight to it.